Literature DB >> 3950058

Postburn serum drug binding and serum protein concentrations.

D C Bloedow, J F Hansbrough, T Hardin, M Simons.   

Abstract

The free fractions of diazepam, imipramine, lidocaine, meperidine, phenytoin, propranolol, and salicylic acid were determined in the serum of seven burn patients (25% to 80% of their skin surface burned) about one week after the burn and in three of the patients at about four weeks following the injury. Serum protein fractions were measured by electrophoresis, and alpha-1 acid glycoprotein levels were determined. For the drugs that bind predominantly to albumin, the serum free fractions were greater in patients one week after the burn incident than in control subjects (diazepam, 0.055 vs. 0.017; phenytoin, 0.24 vs. 0.16; and salicylic acid, 0.69 vs. 0.32). The increase in free fraction for these drugs was attributed to the postburn decrease in serum albumin levels (2.2 vs. 4.4 g/dL, control). Imipramine, lidocaine, meperidine, and propranolol bind primarily to alpha-1 acid glycoprotein. The free fractions for these drugs decreased one week following the burn (imipramine, 0.074 vs. 0.095; lidocaine, 0.17 vs. 0.35; meperidine, 0.37 vs. 0.48; and propranolol, 0.045 vs. 0.107), presumably in response to the increased alpha-1 acid glycoprotein concentration (222 vs. 83 mg/dL, control). Diazepam, lidocaine, propranolol, and salicylic acid free fractions were still different from control values at four weeks after the accident.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3950058     DOI: 10.1002/j.1552-4604.1986.tb02923.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

4.  Orosomucoid 1 drives opportunistic infections through the polarization of monocytes to the M2b phenotype.

Authors:  Kiwamu Nakamura; Ichiaki Ito; Makiko Kobayashi; David N Herndon; Fujio Suzuki
Journal:  Cytokine       Date:  2015-02-14       Impact factor: 3.861

5.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

6.  Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.

Authors:  P Bourget; A Lesne-Hulin; R Le Reveillé; H Le Bever; H Carsin
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

Authors:  M J Rybak; L M Albrecht; J R Berman; L H Warbasse; C K Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 8.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.